The National Institutes of Health is opening multiple avenues for patient feedback as it increasingly adopts artificial intelligence through initiatives such as the Bio Genesis Mission, according to agency officials speaking at the Special Competitive Studies Project’s AI+ Health Summit. The effort forms part of the agency’s contribution to the broader Genesis Mission backed by the Trump administration.
Patient and Community Co-Design in NIH Artificial Intelligence Programs
Federal health officials are baking direct community involvement into every new computational health program currently under development. Bradley Bower, NIH’s Chief AI Officer, explained the strategy during a panel appearance in Washington, D.C.
“Pretty much every new AI-focused program we’re building up… all of them include a co-design approach where patients, clinicians, anybody that is engaged as a stakeholder in the process has to be involved,” Bower said.
Programs like AIM-AHEAD, which originally started in 2021, work to instill artificial intelligence expertise among biomedical researchers working in underserved communities. Bower noted that these regional networks are currently training researchers to keep everyday patients and local communities closely tied to research initiatives. Other precision medicine programs, including PRIMED-AI and Bridge2AI, also utilize this multi-stakeholder design model to shape advanced machine learning applications.
Did you know?
Programs like Bridge2AI and PRIMED-AI feature a co-design approach where patients, clinicians and other stakeholders shape AI development.
Accelerating Biomedical Innovation Through the Bio Genesis Mission
The push for widespread community inclusion arrives alongside a major federal effort to double the speed of biomedical breakthroughs. Announced in July, the Bio Genesis Mission targets six distinct scientific domains, according to an U.S. Department of Health and Human Services press release.
The targeted domains include predicting living systems, scaling biology for industrial leadership, detecting biological threats early, accelerating drug discovery, unlocking pediatric cancer cures, and uncovering the root causes of chronic disease. Advanced computing tools analyze vast, complex datasets through the initiative, allowing researchers to spot hidden patterns, formulate new hypotheses, and surface novel medical treatments. Federal planners expect tangible results within five to ten years.
Interagency Collaboration With FDA and CMS
Translating laboratory breakthroughs into accessible patient care requires deep coordination across federal health branches. Bower noted that NIH is in the early stages of ironing out official logistics with partner agencies.
“We are early in those conversations, sort of figuring out how all the pieces fit together,” Bower told Nextgov/FCW. He added that leadership is determining how HHS will coordinate these efforts alongside NIH.
During the AI+ Health Summit, Bower pointed to future collaborations with the Food and Drug Administration and the Centers for Medicare and Medicaid Services to fast-track discoveries. The FDA will assist in creating a quicker path to market for new medical innovations. Meanwhile, CMS handles market access by determining Medicare coverage parameters for seniors.
“CMS, FDA, NIH are all interested in making sure things get translated to the market in a safe and effective way, that things are validated appropriately,” Bower said.
Bower expects the agency to establish a solid bureaucratic and technical infrastructure within the next 12 months. This framework aims to lower existing hurdles by streamlining interagency agreements and Memorandums of Understanding across HHS.
Frequently Asked Questions
What is the Bio Genesis Mission?
Announced in July, the Bio Genesis Mission is an NIH initiative designed to double the pace of biomedical innovation using advanced artificial intelligence across six key health and biology domains.
How are patients involved in NIH artificial intelligence projects?
According to NIH Chief AI Officer Bradley Bower, new AI programs utilize a co-design model. This requires ongoing collaboration with patients, clinicians, and community stakeholders.
Which federal agencies are collaborating on these AI health initiatives?
The NIH is working alongside the FDA, CMS, and the Advanced Research Projects Agency for Health to validate tools and accelerate the path to market for new treatments.
What are your thoughts on integrating patient feedback into federal healthcare algorithms? Let us know in the comments below, and explore our health tech news archive for more updates on federal AI policy.
Keep reading